European consensus statement on the terminology used in the management of lupus glomerulonephritis. - Wikidata - wikimedia - TriplyDB

European consensus statement on the terminology used in the management of lupus glomerulonephritis.

European consensus statement on the terminology used in the management of lupus glomerulonephritis.

http://www.wikidata.org/entity/Q37391863

about

Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies Role of early repeated renal biopsies in lupus nephritis.Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis.Value of repeat biopsy in lupus nephritis flares Toward the development of criteria for global flares in juvenile systemic lupus erythematosus Measuring eosinophiluria, urinary eosinophil cationic protein and urinary interleukin-5 in patients with Lupus Nephritis IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment.Random spot urine protein/creatinine ratio: a reliable method for monitoring lupus nephritis?Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up Lupus nephritis is associated with poor pregnancy outcomes in pregnant SLE patients in Cape Town: a retrospective analysis.Clinical features, epidemiology, and short-term outcomes of proliferative lupus nephritis in Eastern India.Urinary CD8+ T-cell counts discriminate between active and inactive lupus nephritis.Interferon (IFN)-λ is a potential mediator in lupus nephritis Treatment of proliferative lupus nephritis: a slowly changing landscape.Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis.Diagnosis and treatment of lupus nephritis flares--an update.Pediatric lupus nephritis: more options, more chances?Lupus nephritis: review of the literature.Optimizing pharmacotherapy of systemic lupus erythematosus: the pharmacist role.The multifaceted aspects of refractory lupus nephritis.Reviewing the recommendations for lupus in children.Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review.Lupus nephritis management guidelines compared.Renal outcome after kidney-transplantation in Korean patients with lupus nephritis.Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis.Long-term Outcome of Lupus Nephritis Class II in Argentine Patients: An Open Retrospective Analysis.Understanding remission in real-world lupus patients across five European countries.Renal flare prediction and prognosis in lupus nephritis Hispanic patients.Remission of proteinuria indicates good prognosis in patients with diffuse proliferative lupus nephritis.A decade of mycophenolate mofetil for lupus nephritis: is the glass half-empty or half-full?Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases.Mycophenolate mofetil versus intravenous cyclophosphamide for induction treatment of proliferative lupus nephritis in a Japanese population: a retrospective study.Soluble receptor for advanced glycation end products alleviates nephritis in (NZB/NZW)F1 mice.Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response.Attenuation of nephritis in lupus-prone mice by thalidomide.Rheumatoid factor false positivity in patients with ANCA-associated vasculitis not having medical conditions producing rheumatoid factor.ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap.

P2860

Q34157817-8F9BCCE0-DC0F-4E01-9299-5703B7A85B35 Q34187282-ABF36013-A836-40ED-BB52-1622644A593E Q34424633-3EC036DD-4B9E-4F44-AD9E-2CF9B9C3F728 Q34462600-9702C51F-AA78-4A46-A6C6-A20EA176E798 Q34478821-DDCA8BEB-8C5A-4E3D-BAE4-A6278E7385B6 Q34626276-B1B2351A-E3BB-400B-820A-6366161114E5 Q34720728-4335306D-1C59-45D2-896D-D13F6AF69BA1 Q35078183-4408ADFE-4710-47EE-B578-6DD87141C2ED Q35626485-2E242FDD-BF88-40A6-8AEB-E53C52A95988 Q36085036-3D93BC56-F8DF-4123-AE01-D0231B0028C6 Q36278355-972EB87C-E643-4988-A49D-8490496AB5A8 Q36477390-1D21B12A-C2BA-4040-981C-BC8895D34044 Q36680217-DD8DDBE4-2DC5-4C3B-BD56-62AAC068AAC8 Q36752458-E233D1EB-5894-4C44-800A-CA7A8BA88060 Q36903331-EF8CFC81-98ED-4E16-94F1-5B47FFCA8C73 Q37464013-233A5B3E-3AC4-47B4-86CE-8D1B03893C54 Q37822658-05C618C9-0367-4E43-9CF1-8E3B1409FD5D Q38024085-F466A0D4-DBF9-40E4-8983-17F6F0A75257 Q38059445-4B7E0C6A-FBF0-4C6C-9C5D-6DC7EBBEE0F4 Q38102946-4CE9F3A7-4B10-42EE-B448-13EF53350888 Q38162780-76CF541F-5A2A-40AA-A548-DB15A6C05D15 Q38225438-75495016-B5BA-422E-8FA7-701CDE4DF893 Q38285375-98E266FE-94BB-4560-8AE4-657E9D2FE52B Q38374309-8F5B4DC5-B981-4040-B916-BFBDBFA7F88E Q38418254-316AD17C-2E27-447E-867E-F39876ECF72B Q38446941-A9161DAF-DB9F-4580-BB93-55461AAABFCC Q38629081-4F851186-3CF9-428E-91C3-D267B2C85C99 Q38777083-987A814A-CEB0-4DD5-9BBA-EAD42ECA42F5 Q39789199-27F70F95-6366-420B-AB6A-A9E7E8715417 Q40243855-4286BB5C-FC7C-4550-930B-382C7B505875 Q41317916-1330CBAE-3CD2-4BEE-A8DC-4BA1B77BD2CA Q41599627-7B460F05-C489-46B3-97F9-B62CEF0587F6 Q42511206-4362C0C3-2FCC-4C5A-9695-B94B5C6CDCA5 Q43031095-529E2C07-904D-437C-B4A6-EDA6B7123BB1 Q44606491-CBA7559E-5896-487E-8079-83D8F9A3C16E Q45090317-57F6E0CB-F215-4AD7-9B57-D9345431A835 Q46260498-F63B86F3-0B29-4367-9F40-C7A24CB0292E Q47220547-BA2F0790-BB8D-4E53-B91B-624505D241CD Q48337165-6C9BACA2-3DA7-40CA-ACA1-CF9DF2CBCE45 Q49215238-8F9851A8-84BE-45F6-997A-297E8DE16B91

P2860

European consensus statement on the terminology used in the management of lupus glomerulonephritis.

http://www.wikidata.org/entity/Q37391863

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

European consensus statement o ...... t of lupus glomerulonephritis.

@en

European consensus statement o ...... t of lupus glomerulonephritis.

@nl

type

label

European consensus statement o ...... t of lupus glomerulonephritis.

@en

European consensus statement o ...... t of lupus glomerulonephritis.

@nl

prefLabel

European consensus statement o ...... t of lupus glomerulonephritis.

@en

European consensus statement o ...... t of lupus glomerulonephritis.

@nl

P1433

Q37391863-8CA577D7-D747-45E7-B4B9-F1768ECD8A63

P1476

Q37391863-23DC90E5-559D-483E-8D4E-C7605C0A2E12

P2093

Q37391863-0DBBB866-AA8D-4F93-83D8-DB2A395AFB15

Q37391863-159D8504-A5EF-408C-8CA6-0FFC42641125

Q37391863-365FBE54-380B-4BB0-A168-24AD11E188C6

Q37391863-401A6030-92FE-42B4-ABC3-D700511FFECA

Q37391863-4D231F7A-F9D9-42FE-A31A-B6D29BC6C5CB

Q37391863-55219EB4-D64C-46AD-8645-73F605D748E7

Q37391863-60211F4C-A837-4DAF-8AC3-FA5F304FB5C3

Q37391863-62C0ACDF-A10D-401E-8494-DCC3E6FE2F48

Q37391863-70ADE16D-603B-4282-9DA5-6A617528AD07

Q37391863-75D9AAAE-2DFC-4276-9860-312B2F5DAF61

P2860

Q37391863-0B35A960-327E-45F0-AE14-03D0916F0570

Q37391863-0BD75B27-38D0-48EE-9698-C74797AEC7B5

Q37391863-1AD9B819-34D8-4D5D-B638-2B4E41A3D0C3

Q37391863-263FEB07-6611-472E-9C87-417E6B438F06

Q37391863-30D02D1E-63D7-4F7C-82DB-91A5EC1C53DC

Q37391863-3D94546A-A618-4F98-9763-753EF4E0DDE3

Q37391863-52E83C56-B6A2-40BD-9D23-6BB3CE5FC32C

Q37391863-57722FE3-E1F8-42B7-A634-B306E3A3315A

Q37391863-585E5F92-218E-4302-92E4-8D42E65316BF

Q37391863-71A27743-BA60-451C-A152-23B1A9B21EDB

P304

Q37391863-75062FB2-0F18-4A9C-BFCC-DB1C4231E66F

P31

Q37391863-106B9AE0-3F14-4E3B-BC66-72BCFB4D96CA

P356

Q37391863-B8AAA07B-79CB-4119-B1CF-7EDED5A51EB6

P433

Q37391863-49957BBA-B4BB-40D8-A66A-EC285BF6A021

P478

Q37391863-FE012532-7BCA-40FC-BF8C-F48FEDC391D3

P50

Q37391863-1CEFAE9A-4BFC-4A38-909A-E1E4C5BD7B2F

Q37391863-2A1E1E08-465B-43B8-9479-3F97FA8BCE77

Q37391863-354FC89C-B377-4F5D-8EF7-6E7B5BDCD63E

Q37391863-452623D9-276B-4034-A997-37044032E228

Q37391863-8B16B5C0-D3A4-4615-BE49-4D5C76E39C54

Q37391863-9CB91D5F-B5DE-4B2B-927C-370D981CA434

Q37391863-CD37DE83-A7E5-4A8A-80A8-61DA577D3A71

Q37391863-DF5D5E81-FA2C-4BDE-804A-911264EAE270

Q37391863-EF777894-23CC-4725-86F7-1D2194961B35

Q37391863-F37C5279-0863-444B-94FC-285BCC77927B

P577

Q37391863-0E30161C-4FF1-4861-9C95-A44817B65BDB

P5875

Q37391863-53A629B2-D109-47A1-B465-7F4455E7E465

P698

Q37391863-C78E97B7-BBF1-45E3-87B8-57835619AB49

P921

Q37391863-16BE2022-17DE-4D49-8210-5F47988BB6D5

P356

0961203308100481

P1433

P1476

European consensus statement o ...... t of lupus glomerulonephritis.

@en

P2093

B Moulin

http://www.w3.org/2001/XMLSchema#string

C Chizzolini

http://www.w3.org/2001/XMLSchema#string

C Pusey

http://www.w3.org/2001/XMLSchema#string

D Adu

http://www.w3.org/2001/XMLSchema#string

D Jayne

http://www.w3.org/2001/XMLSchema#string

F Ferrario

http://www.w3.org/2001/XMLSchema#string

F Hiepe

http://www.w3.org/2001/XMLSchema#string

F Houssiau

http://www.w3.org/2001/XMLSchema#string

H Schulze-Koops

http://www.w3.org/2001/XMLSchema#string

J Ballerin

http://www.w3.org/2001/XMLSchema#string

P2860

The 1982 revised criteria for the classification of systemic lupus erythematosus

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Cardiovascular risk factors and the long-term outcome of lupus nephritis.

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.

Therapeutic options for resistant lupus nephritis.

Update on the treatment of lupus nephritis.

Thirty years of cyclophosphamide: assessing the evidence.

From BILAG to BLIPS--disease activity assessment in lupus past, present and future.

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

P304

257-263

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0961203308100481

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Pier Luigi Meroni

Carlos Vasconcelos

Caroline Gordon

Graham R. V. Hughes

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24004920

http://www.w3.org/2001/XMLSchema#string

P698

19213865

http://www.w3.org/2001/XMLSchema#string

P921

glomerulonephritis